Table 1 Characteristics of the participants from the study of patient households
Participant ID | Age/gender | Total number of wipe samples | First sampling | Second control sampling | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Therapy A (CP, DOX, EPI, FU, IRI, Pt) | Therapy B (PX, Pt) | |||||||||||||
ADs | Administered doses (mg) | Sampling day/the last cycle before sampling | Number of wipe samples | Positive samples | ADs | Administered doses (mg) | Sampling day/the last cycle before sampling | Number of wipe sample | Positive samples | Number of wipe sample | Positive samples | |||
1 | 68/F | 23 | CP/DOX | 1000/100 | 3/1, 6/2, 31/4 | 14 | 11 | PX | 133 | 3/2 | 5 | 1 | 5 | 1 |
2 | 39/F | 12 | CP/DOX | 858/86 | 3/4, 51/4 | 8 | 8 | PX/Pt | 115/235 | 2/6 | 4 | 3 | 4 | 1 |
3 | 48/F | 9 | CP/DOX | 1000/100 | 1/3 | 4 | 4 | – | – | – | – | – | 5 | 1 |
4 | 55/F | 8 | CP/DOX | 990/99 | 1/3 | 4 | 4 | PX | 133 | – | – | – | 4 | 1 |
5 | 49/F | 8 | CP/DOX | 1090/109 | 10/3 | 4 | 3 | – | – | – | – | – | 4 | 0 |
6 | 35/F | 8 | CP/DOX | 1100/110 | 4/2 | 4 | 3 | – | – | – | – | – | 4 | 1 |
7 | 43/F | 8 | CP/DOX | 984/98 | 7/2 | 4 | 4 | – | – | – | – | – | 4 | 0 |
8 | 38/F | 8 | CP/DOX | 1020/102 | ½ | 4 | 3 | PX | 138 | – | – | – | 4 | 0 |
9 | 34/F | 9 | CP/DOX | 918/92 | 1/3 | 5 | 3 | PX | 122 | – | – | – | 4 | 0 |
10 | 40/F | 5 | CP/DOX | 1128/113 | 76/4 | 5 | 0 | PX | 151 | 6/9 | 5 | 0 | – | – |
11a | 40/F | 6a | CP/DOX | 1140/114 | 24/4a | 4a | 2a | PX | 152 | 3/1a | 4 | 0a | 2a | 0a |
12 | 73/F | 5 | CP/DOX | 960/96 | 1/2 | 5 | 5 | PX/Pt | 128/212 | – | – | – | – | – |
13 | 43/F | 4 | CP/EPI | 1303/157 | 29/4 | 4 | 0 | PX | 127 | 1/2 | 4 | 0 | – | – |
14 | 42/F | 4 | CP/DOX | 900/90 | 44/4 | 4 | 0 | PX | 120 | 1/5 | 4 | 0 | – | – |
15 | 37/F | 4 | CP/DOX | 978/98 | 2/2 | 4 | 4 | PX | 129 | – | – | – | – | – |
16 | 75/M | 4 | Pt/FU/IRI | 135/3724/229 | 5/5 | 4 | 2 | – | – | – | – | – | – | – |
17 | 45/F | 8 | CP/DOX | 1068/107 | 5/2 | 4 | 3 | PX | 144 | – | – | – | 4 | 0 |